TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01822886
Drug: Romidepsin + Gemcitabine
Normalized name: Romidepsin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
Study: NCT00887822
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
Study: NCT00887822
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Study: NCT02382419
Drug: carrageenan-containing gel
Normalized name: Carrageenan
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied vaginally
Study: NCT02063802
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
Study: NCT00719706
Drug: acetyl-l-carnitine PLUS alpha-lipoic acide
Normalized name: acetyl-L-carnitine
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
Study: NCT01110603
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
Study: NCT01110603
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
Study: NCT01452685
Drug: TAK-385
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT01452685
Drug: TAK-385
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT01452685
Drug: TAK-385
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT01452685
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
Study: NCT04220502
Drug: Magic Shave Powder Gold
Normalized name: Boo-Boo Magic
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depilatory Cream for facial hair removal
Study: NCT04276493
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04276493
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01144897
Drug: Carbon-11 labeled Acetate
Normalized name: Carbon-11 Metformin
DrugBank: Metformin C-11 (DB15181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-11 Acetate is a radiotracer used in PET scanning
Study: NCT02083406
Drug: 960mg PQP
Normalized name: pegvaliase-pqpz
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01917799
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg tab of LDA once daily for 7 months
Study: NCT01102439
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg loading dose, then 75 mg daily
Study: NCT01102439
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
Study: NCT01102439
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 mg daily
Study: NCT01102439
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325 mg daily
Study: NCT03682471
Drug: Deoxycholic acid Injection
Normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for subcutaneous injection.
Study: NCT02163447
Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02163447
Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Normalized name: methyl-dihydroartemisinine
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02163447
Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
Normalized name: Fansidar 500/25 (sulfadoxine / pyrimethamine) Oral Tablet
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02163447
Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02163447
Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Normalized name: methyl-dihydroartemisinine
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03437980
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
Study: NCT02681094
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg, orally, Green, plain, diamond-shaped, film-coated tablet
Study: NCT02681094
Drug: Placebo for Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
Study: NCT02681094
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
Study: NCT02681094
Drug: Placebo for Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
Study: NCT02138929
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
Study: NCT03104270
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
Study: NCT03104270
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide PO at 3mg
Study: NCT03104270
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
Study: NCT03104270
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
Study: NCT01593566
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Femoral nerve block using 0.25% versus 0.5% bupivacaine
Study: NCT01593566
Drug: 0.5% Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
Study: NCT06282731
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Indications:Benign prostate hyperplasia
Study: NCT02027324
Drug: Chlorhexidine-alcohol group
Normalized name: chlorhexidine / isopropyl alcohol
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
Study: NCT02027324
Drug: Povidone-Iodine Group
Normalized name: Povidone-Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
Study: NCT00000610
Drug: magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02159911
Drug: Misoprostol administered orally one hour before surgery
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient.
Study: NCT03821233
Drug: ZW49
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~* Expansion: MTD or RD identified in the dose-escalation part of the study
Study: NCT03163277
Drug: emtricitabine, darunavir/cobicistat, maraviroc
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment change
Study: NCT03497975
Drug: Nalbuphine ER Tablets
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Nalbuphine ER Tablets
Study: NCT03497975
Drug: Nalbuphine ER Tablets
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open Label Extension
Study: NCT04123379
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection
Study: NCT04123379
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg oral twice a day for 28 days
Study: NCT03907072
Drug: WVE-210201 (suvodirsen)
Normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)
Study: NCT00389909
Drug: Doxapram
Normalized name: Doxapram
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender.
Study: NCT04123379
Drug: BMS-986253
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2400mg once by injection
Study: NCT00568399
Drug: sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
Study: NCT00286468
Drug: Alogliptin and glyburide
Normalized name: metformin and alogliptin
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
Study: NCT04212026
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
Study: NCT01552408
Drug: 0.3 mg ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
Study: NCT00286468
Drug: Alogliptin and glyburide
Normalized name: metformin and alogliptin
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
Study: NCT00286468
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
Study: NCT04586920
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03389490
Drug: Insulin Glargine 300 UNT/ML
Normalized name: insulin glargine 300 UNT/ML
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self titration of insulin glargine U300
Study: NCT03389490
Drug: Neutral protamine hagedorn insulin
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self titration of NPH insulin
Study: NCT01074086
Drug: RAD 001
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
Study: NCT04586920
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT02744053
Drug: Technetium Tc-99m Sestamibi
Normalized name: TECHNETIUM TC-99M SESTAMIBI
DrugBank: Technetium Tc-99m sestamibi (DB09161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via injection
Study: NCT04090294
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months
Study: NCT00072462
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20mg + Anastrozole placebo
Study: NCT00072462
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 1mg + Tamoxifen placebo
Study: NCT04026113
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
Study: NCT00687596
Drug: TAC-101
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
Study: NCT04861103
Drug: Lovenox
Normalized name: Lovenox
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a day dosing and measuring Xa peak and trough levels
Study: NCT03036098
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified Dose on Specified Days
Study: NCT03036098
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT03036098
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified Dose on Specified Days
Study: NCT04230759
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
Study: NCT02347345
Drug: Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
Normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
Study: NCT03970330
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.5mg daily dose, taken orally
Study: NCT03970330
Drug: Norethindrone Acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 - 15mg daily dose, taken orally
Study: NCT04599543
Drug: IL3 CAR T-cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive IL3 CAR T-cells by intravenous infusion
Study: NCT00044811
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00733096
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two transforaminal epidural injections of 4 mg, two weeks apart
Study: NCT00733096
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two transforaminal epidural steroid injections with 60 mg, two weeks apart
Study: NCT03485976
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment at the FDA-approved psoriasis dosing
Study: NCT04073290
Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN]
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
Study: NCT04073290
Drug: Lactulose 667 milligram/milliliter Oral Solution
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
Study: NCT04544969
Drug: cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge.
Study: NCT04055220
Drug: Treatment by Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;
Study: NCT04171219
Drug: Talabostat Mesylate
Normalized name: mesylate
DrugBank: Talabostat (DB06182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02745093
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
Study: NCT02745093
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
Study: NCT04467138
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
Study: NCT02132312
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00336986
Drug: recombinant interleukin-21
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02394457
Drug: Cosyntropin
Normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Drug Infusion over 1 hour and a half
Study: NCT01883596
Drug: 0.12% chlorhexidine solution
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bexident® (0.12% chlorhexidine solution)